← Back to Patent Explorer
US4673566A Expired / Lapsed US ⏱️ 0.0 years remaining

Microencapsulation of living tissue and cells

Assignee: Sanofi Pasteur Ltd
•
Filing: 1984-05-24
•
Granted: 1987-06-16
•
Expires: 2004-05-24
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Living tissue or cells, for example, islets of Langerhans, are microencapsulated for implantation in the body for long term treatment of diabetes or other disease requiring organ transplantation. The microcapsules take the form of a biocompatible semi-permeable hydrogel membrane based on polylysine which permits the passage of materials and oxygen to the cells and metabolic products from the cells while retaining the cells encapsulated. The biocompatible semi-permeable membrane has an outer negatively-charged surface, which, combined with a controlled thickness of polylysine of molecular weight from 10,000 to 30,000 daltons, imparts to the microcapsules the ability to maintain long term effectiveness.

Inventors

  • 👤 Mattheus F. A. Goosen
  • 👤 Geraldine M. O'Shea
  • 👤 Anthony M. Sun

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 10:46
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/14; A61K9/16; A61K9/1605; A61K9/1629; A61K9/1652; A61K9/48; A61K9/50; A61K9/5005; A61K9/5021; A61K9/5031; A61K9/5036; A61K9/5073; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/29

Claims Analysis

Total Claims: 32
Claim 1
Independent Claim 170 words
A microcapsule having a diameter of about 500 to about 2000 μm and suitable for implantation into an animal body, comprising: a core comprising one or more viable, healthy, physiologically-active tissue cells capable of ongoing metabolism, and a biocompatible semi-permeable membrane surrounding and enclosing said core, said semi-permeable membrane being permeable to tissue nutrients and metabolic products produced by the tissue but impermeable to immune system proteins, said semi-permeable membrane having a molecular weight cut-off of below about 150,000 daltons, said biocompatible membrane being a hydrogel formed by ionic reaction between a polylysine polymer having a molecular weight from about 10,000 to about 30,000 daltons and a polymeric material bearing negatively-charged groups to provide an outer negatively-charged surface, said polylysine polymer membrane having a durability sufficient to permit said microcapsules to be injected in the animal body and sufficient to maintain said microcapsules in an intact form and to permit said tissue to effect ongoing metabolism when injected into the animal body for a period of time exceeding three months.
Claim 2
Dependent Claim 170 words
A microcapsule having a diameter of about 500 to about 2000 μm and suitable for implantation into an animal body, comprising: a core comprising one or more viable, healthy, physiologically-active tissue cells capable of ongoing metabolism, and a biocompatible semi-permeable membrane surrounding and enclosing said core, said semi-permeable membrane being permeable to tissue nutrients and metabolic products produced by the tissue but impermeable to immune system proteins, said semi-permeable membrane having a molecular weight cut-off of below about 150,000 daltons, said biocompatible membrane being a hydrogel formed by ionic reaction between a polylysine polymer having a molecular weight from about 10,000 to about 30,000 daltons and a polymeric material bearing negatively-charged groups to provide an outer negatively-charged surface, said polylysine polymer membrane having a durability sufficient to permit said microcapsules to be injected in the animal body and sufficient to maintain said microcapsules in an intact form and to permit said tissue to effect ongoing metabolism when injected into the animal body for a period of time exceeding three months.
Claim 3
Dependent Claim 13 words
The microcapsule of claim 1 wherein said tissue cells are islets of Langerhans.
Claim 4
Dependent Claim 15 words
The microcapsule of claim 1 wherein said negatively charged groups are carboxyl or hydroxyl groups.
Claim 5
Dependent Claim 26 words
The microcapsule of claim 3 wherein said polymeric material bearing negatively charged groups is selected from the group consisting of alginate, polyvinyl alcohol or polylactic acid.
Claim 6
Dependent Claim 18 words
The microcapsule of claim 4 wherein said polylysine has a molecular weight of about 15,000 to about 25,000.
Claim 7
Dependent Claim 15 words
The microcapsule of claim 5 wherein said polylysine has a molecular weight of about 17,000.
Claim 8
Dependent Claim 27 words
The microcapsule of claim 1 having a diameter of about 700 to about 1000 μm and wherein said semi-permeable membrane has a thickness of about 5 μm.
Claim 9
Dependent Claim 17 words
The microcapsule of claim 1 wherein said membrane has a molecular weight cut-off of about 67,000 daltons.
Claim 10
Dependent Claim 26 words
The microcapsule of claim 1 wherein said core also comprises an aqueous medium of nutrients sufficient to maintain said tissue cells and allow normal metabolism thereof.
Claim 11
Independent Claim 205 words
A method of encapsulating a core material within a semi-permeable membrane to form microcapsules for implantation into an animal body, which comprises: (a) placing the material in an aqueous solution of a water-soluble polymeric substance that can be reversibly gelled and which has free acid groups, (b) forming the solution into droplets, (c) gelling the droplets to produce discrete shape-retaining temporary capsules, (d) forming semi-permeable membranes about the temporary capsules by contact between the temporary capsules and a polymer containing free amino groups to cause ionic reaction with the acid groups in a surface layer of the capsule, said polymer containing free amino groups being polylysine having a molecular weight of about 10,000 to about 30,000 daltons, said contact being effected for a period of time no less than about four minutes sufficient to provide a polymer coating on the temporary capsule of sufficient durability to permit the microcapsules to be injected into the animal body, and (e) contacting said microcapsules formed in step (d) with a biocompatible polymeric material which contains free negatively-charged groups capable of ionic reaction with the free amino groups in a surface layer of the microcapsule, thereby to form an outer coating of said biocompatible polymeric material on said microcapsules.
Claim 12
Independent Claim 205 words
A method of encapsulating a core material within a semi-permeable membrane to form microcapsules for implantation into an animal body, which comprises: (a) placing the material in an aqueous solution of a water-soluble polymeric substance that can be reversibly gelled and which has free acid groups, (b) forming the solution into droplets, (c) gelling the droplets to produce discrete shape-retaining temporary capsules, (d) forming semi-permeable membranes about the temporary capsules by contact between the temporary capsules and a polymer containing free amino groups to cause ionic reaction with the acid groups in a surface layer of the capsule, said polymer containing free amino groups being polylysine having a molecular weight of about 10,000 to about 30,000 daltons, said contact being effected for a period of time no less than about four minutes sufficient to provide a polymer coating on the temporary capsule of sufficient durability to permit the microcapsules to be injected into the animal body, and (e) contacting said microcapsules formed in step (d) with a biocompatible polymeric material which contains free negatively-charged groups capable of ionic reaction with the free amino groups in a surface layer of the microcapsule, thereby to form an outer coating of said biocompatible polymeric material on said microcapsules.
Claim 13
Dependent Claim 25 words
The method of claim 10 wherein said core material comprises living tissue which is in finely-divided suspended form in said aqueous solution in step (a).
Claim 14
Dependent Claim 34 words
The method of claim 11 wherein said living tissue comprises islets of Langerhans whereby said microcapsules may be used to control blood sugar levels in diabetic animal bodies into which the microcapsules are implanted.
Claim 15
Dependent Claim 14 words
The method of claim 10 wherein said reversibly-gellable water-soluble substance is a polysaccharide gum.
Claim 16
Dependent Claim 13 words
The method of claim 13 wherein said gum is an alkali metal alginate.
Claim 17
Dependent Claim 19 words
The method of claim 10 wherein said polylysine has a molecular weight of about 15,000 to about 25,000 daltons.
Claim 18
Dependent Claim 29 words
The method of claim 10 wherein said contact in step (d) is effected for a period of time sufficient to provide a polylysine layer of thickness about 5 μm.
Claim 19
Dependent Claim 28 words
The method of claim 10 wherein said contact in step (d) is effected by contact with an aqueous solution of polylysine at about 6 to about 9 minutes.
Claim 20
Dependent Claim 20 words
The method of claim 17, wherein said aqueous solution of polylysine has a concentration of at least about 0.05 wt.%.
Claim 21
Dependent Claim 31 words
The method of claim 10 wherein said biocompatible negatively-charged polymeric material is selected from the group consisting of polyvinyl alcohols having free hydroxyl groups and polylactic acids containing free acid groups.
Claim 22
Dependent Claim 21 words
The method of claim 10 wherein said reversibly-gellable water-soluble substance comprises sodium alginate, and said biocompatible polymeric material comprises sodium alginate.
Claim 23
Dependent Claim 37 words
The method of claim 14 wherein said alkali metal alginate is sodium alginate and the viscosity of said aqueous solution of sodium alginate is at least sufficient to result in the formation of substantially spherical temporary capsules.
Claim 24
Dependent Claim 20 words
The method of claim 21 wherein said aqueous sodium alginate solution has a viscosity of at least about 30 cps.
Claim 25
Dependent Claim 17 words
The method of claim 10 including the further step of reliquifying the gel within the semi-permeable membrane.
Claim 26
Dependent Claim 135 words
A tissue implantation method, which comprises: encapsulating tissue within a spherical microcapsule having a diameter of about 500 to about 2000 μm and a biocompatible semipermeable membrane having a negatively-charged biocompatible outer surface and a thickness of about 5 microns, said biocompatible membrane having a molecular weight cut-off below 150,000 daltons and being impermeable to immune system proteins but permeable to tissue nutrients and metabolic products produced by the tissue, said biocompatible semipermeable membrane being a hydrogel formed by ionic reaction between a polylysine polymer having a molecular weight from about 10,000 to about 30,000 daltons and a polymeric material being negatively charged groups and further comprising an outer, negatively charged surface and introducing said microcapsule into a mammalian body to effect ongoing metabolism in said body for a period of time exceeding three months.
Claim 27
Dependent Claim 135 words
A tissue implantation method, which comprises: encapsulating tissue within a spherical microcapsule having a diameter of about 500 to about 2000 μm and a biocompatible semipermeable membrane having a negatively-charged biocompatible outer surface and a thickness of about 5 microns, said biocompatible membrane having a molecular weight cut-off below 150,000 daltons and being impermeable to immune system proteins but permeable to tissue nutrients and metabolic products produced by the tissue, said biocompatible semipermeable membrane being a hydrogel formed by ionic reaction between a polylysine polymer having a molecular weight from about 10,000 to about 30,000 daltons and a polymeric material being negatively charged groups and further comprising an outer, negatively charged surface and introducing said microcapsule into a mammalian body to effect ongoing metabolism in said body for a period of time exceeding three months.
Claim 28
Dependent Claim 12 words
The method of claim 24 wherein said microcapsule is introduced by injection.
Claim 29
Dependent Claim 16 words
The method of claim 24 wherein said tissue comprises islets of Langerhans or a fraction thereof.
Claim 30
Dependent Claim 12 words
The method of claim 24 wherein said microcapsule is substantially perfectly spherical.
Claim 31
Dependent Claim 11 words
The method of claim 24 wherein said tissue comprises liver cells.
Claim 32
Dependent Claim 19 words
The method of claim 24 wherein said membrane has a molecular weight cut-off of less than about 67,000 daltons.

References Cited (Backward Citations)

US4352883A Cited
US4391909A Cited
US4409331A Cited
US4407957A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1990-06-15 1990-12-15 1991-06-16 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1994-06-15 1994-12-15 1995-06-16 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1998-06-15 1998-12-15 1999-06-16 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag